[Skip to Navigation]
Evidence to Practice
December 14, 2020

Compounded Bioidentical Hormone Therapy: The National Academies Weigh In

Author Affiliations
  • 1Department of Medicine, University of California, San Diego, School of Medicine, La Jolla
  • 2Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
JAMA Intern Med. 2021;181(3):370-371. doi:10.1001/jamainternmed.2020.7232

On July 1, 2020, the National Academies of Sciences, Engineering, and Medicine (NASEM) published The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use,1 a report commissioned in September 2018. The US Food and Drug Administration (FDA) charged the NASEM to summarize the available evidence on compounded bioidentical hormone therapy (cBHT) and develop recommendations on the clinical utility of cBHT drug products, whether the current safety and effectiveness evidence supports use of these products to treat patients, and the patient populations that might require a cBHT drug product in place of an FDA-approved drug product.1

Add or change institution